NO996429L - 2-substituerte 4,5-diarylimidazoler - Google Patents

2-substituerte 4,5-diarylimidazoler

Info

Publication number
NO996429L
NO996429L NO996429A NO996429A NO996429L NO 996429 L NO996429 L NO 996429L NO 996429 A NO996429 A NO 996429A NO 996429 A NO996429 A NO 996429A NO 996429 L NO996429 L NO 996429L
Authority
NO
Norway
Prior art keywords
diarylimidazoles
substituted
Prior art date
Application number
NO996429A
Other languages
English (en)
Other versions
NO996429D0 (no
Inventor
Lsszlo Revesz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO996429L publication Critical patent/NO996429L/no
Publication of NO996429D0 publication Critical patent/NO996429D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
NO996429A 1997-06-30 1999-12-23 2-substituerte 4,5-diarylimidazoler NO996429D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9713726.9A GB9713726D0 (en) 1997-06-30 1997-06-30 Organic compounds
PCT/EP1998/003930 WO1999001449A1 (en) 1997-06-30 1998-06-26 2-substituted 4,5-diaryl imidazoles

Publications (2)

Publication Number Publication Date
NO996429L true NO996429L (no) 1999-12-23
NO996429D0 NO996429D0 (no) 1999-12-23

Family

ID=10815101

Family Applications (1)

Application Number Title Priority Date Filing Date
NO996429A NO996429D0 (no) 1997-06-30 1999-12-23 2-substituerte 4,5-diarylimidazoler

Country Status (28)

Country Link
US (1) US6300347B1 (no)
EP (2) EP1396491A3 (no)
JP (1) JP3704362B2 (no)
KR (1) KR20010013215A (no)
CN (1) CN1261885A (no)
AR (1) AR014886A1 (no)
AT (1) ATE275557T1 (no)
AU (1) AU744411B2 (no)
BR (1) BR9810955A (no)
CA (1) CA2291758A1 (no)
CO (1) CO4940462A1 (no)
DE (1) DE69826127T2 (no)
ES (1) ES2226164T3 (no)
GB (1) GB9713726D0 (no)
HU (1) HUP0003351A3 (no)
ID (1) ID23385A (no)
IL (1) IL133034A0 (no)
NO (1) NO996429D0 (no)
NZ (1) NZ501275A (no)
PE (1) PE99999A1 (no)
PL (1) PL337057A1 (no)
PT (1) PT993456E (no)
RU (1) RU2214408C2 (no)
SK (1) SK186599A3 (no)
TR (1) TR199903278T2 (no)
TW (1) TW429258B (no)
WO (1) WO1999001449A1 (no)
ZA (1) ZA985656B (no)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998007425A1 (en) 1996-08-21 1998-02-26 Smithkline Beecham Corporation Imidazole compounds, compositions and use
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
EP1119254A4 (en) 1998-10-07 2004-05-12 Smithkline Beecham Corp STROKE TREATMENT
EP1143957A3 (en) * 1998-12-16 2002-02-27 Warner-Lambert Company Treatment of arthritis with mek inhibitors
ATE425142T1 (de) * 1999-04-23 2009-03-15 Vertex Pharma Inhibitoren von c-jun n-terminal kinasen (jnk)
HUP0203766A3 (en) * 1999-04-23 2008-01-28 Takeda Pharmaceutical 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof and pharmaceutical compositions containing them
US6291457B1 (en) * 1999-07-01 2001-09-18 Merck & Co., Inc. Compounds having cytokine inhibitory activity
US7122666B2 (en) 1999-07-21 2006-10-17 Sankyo Company, Limited Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
ATE311385T1 (de) * 1999-10-27 2005-12-15 Novartis Pharma Gmbh Thiazol und imidazo(4,5-b)pyridin verbindungen und ihre verwendung als pharmazeutika
US6610697B1 (en) * 1999-11-10 2003-08-26 Ortho-Mcneil Pharmaceutical, Inc. Substituted 2-aryl-3-(heteroaryl)-imidazo[1,2-a]pyrimidines, and related pharmaceutical compositions and methods
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
ES2228629T3 (es) 1999-11-22 2005-04-16 Smithkline Beecham Plc Derivados de imidazol y su uso como inhibidores de raf-quinasa.
WO2001038312A1 (en) 1999-11-23 2001-05-31 Smithkline Beecham Corporation 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/p38 KINASE INHIBITORS
US7612065B2 (en) 2000-04-21 2009-11-03 Vertex Pharmaceuticals Incorporated Inhibitors of c-JUN N-terminal kinases (JNK)
KR20030080087A (ko) 2001-03-09 2003-10-10 화이자 프로덕츠 인코포레이티드 항염증제로서의 트리아졸로피리딘
AP2002002460A0 (en) 2001-03-09 2002-06-30 Pfizer Prod Inc Novel benzimidazole anti-inflammatory compounds.
DE60205974T2 (de) 2001-04-04 2006-06-29 Pfizer Products Inc., Groton Neue Benzotriazole mit entzündungshemmender Wirkung
PT2087908T (pt) 2001-06-26 2018-07-16 Amgen Inc Anticorpos contra opgl
CN100402521C (zh) * 2001-10-22 2008-07-16 田边制药株式会社 4-咪唑啉-2-酮化合物
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
DE10222103A1 (de) * 2002-05-17 2003-11-27 Merckle Gmbh Chem Pharm Fabrik 2-Thio-substituierte Imidazolderivate und ihre Verwendung in der Pharmazie
JP2005538066A (ja) 2002-07-09 2005-12-15 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 新規な抗コリン作用薬及びｐ３８キナーゼ阻害剤を用いた新規な医薬組成物
US6949652B2 (en) 2002-08-30 2005-09-27 Pfizer, Inc. Crystalline forms of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo-[4,3-A]pyridine
US7012143B2 (en) 2002-08-30 2006-03-14 Dombroski Mark A Cycloalkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines
US7005523B2 (en) 2002-08-30 2006-02-28 Pfizer Inc. Cycloalkyl-[4-(trifluorophenyl)-oxazol-5yl]-triazolo-pyridines
US7037923B2 (en) 2002-08-30 2006-05-02 Pfizer, Inc. Alkyl-[4-(trifluorophenyl)-oxazol-5-yl]-triazolo-pyridines
PA8579601A1 (es) 2002-08-30 2004-05-07 Pfizer Prod Inc Compuestos antiinflamatorios de di y trifloruro-triazolo-piridinas
UA80295C2 (en) 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
WO2004053107A2 (en) * 2002-12-06 2004-06-24 Scios Inc. Methods for treating diabetes
AU2003300076C1 (en) 2002-12-30 2010-03-04 Angiotech International Ag Drug delivery from rapid gelling polymer composition
WO2004087653A2 (en) * 2003-04-03 2004-10-14 Merck & Co., Inc. 4-ring imidazole derivatives as modulators of metabotropic glutamate receptor-5
US20040229878A1 (en) * 2003-05-13 2004-11-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of P38 kinase
US7344716B2 (en) * 2003-05-13 2008-03-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
US7553827B2 (en) * 2003-08-13 2009-06-30 Depuy Spine, Inc. Transdiscal administration of cycline compounds
US8273347B2 (en) * 2003-05-13 2012-09-25 Depuy Spine, Inc. Autologous treatment of degenerated disc with cells
US8361467B2 (en) 2003-07-30 2013-01-29 Depuy Spine, Inc. Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints
EP1651643A4 (en) * 2003-07-31 2008-10-08 Irm Llc BICYCLIC COMPOUNDS AND COMPOSITIONS USED AS PDF INHIBITORS
CA2540518A1 (en) 2003-10-02 2005-04-07 Irm Llc Compounds and compositions as protein kinase inhibitors
US8895540B2 (en) 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
US7250434B2 (en) 2003-12-22 2007-07-31 Janssen Pharmaceutica N.V. CCK-1 receptor modulators
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
JP4973191B2 (ja) * 2004-11-10 2012-07-11 小野薬品工業株式会社 含窒素複素環化合物およびその医薬用途
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
EP1853581B1 (en) * 2005-02-28 2010-06-02 Merckle Gmbh 2-sulfinyl- and 2-sulfonyl-substituted imidazole derivatives and their use as cytokine inhibitors
CA2623813A1 (en) * 2005-10-03 2007-04-12 Ono Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic compound and pharmaceutical application thereof
ES2380236T3 (es) 2005-10-28 2012-05-09 Takeda Pharmaceutical Company Limited Compuesto de amida heterocíclica y uso del mismo
ES2301380B1 (es) 2006-08-09 2009-06-08 Laboratorios Almirall S.A. Nuevos derivados de 1,7-naftiridina.
ES2320955B1 (es) 2007-03-02 2010-03-16 Laboratorios Almirall S.A. Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
ES2329639B1 (es) 2007-04-26 2010-09-23 Laboratorios Almirall S.A. Nuevos derivados de 4,8-difenilpoliazanaftaleno.
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
MX2009013176A (es) * 2007-06-05 2011-03-02 Western States Biopharmaceuticals Inc Moleculas superficiales que inducen citosinas de celulas t y metodos de uso.
US8986696B2 (en) * 2007-12-21 2015-03-24 Depuy Mitek, Inc. Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints
US20090162351A1 (en) * 2007-12-21 2009-06-25 Depuy Spine, Inc. Transdiscal administration of inhibitors of p38 MAP kinase
EP2108641A1 (en) 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
EP2113503A1 (en) 2008-04-28 2009-11-04 Laboratorios Almirall, S.A. New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
TWI435874B (zh) * 2008-10-31 2014-05-01 Toray Industries 環己烷衍生物及其醫藥用途
EP2322176A1 (en) 2009-11-11 2011-05-18 Almirall, S.A. New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives
WO2011077387A1 (en) * 2009-12-22 2011-06-30 Csir Inhibition of the activity of kinase and synthetase enzymes
JP2013523766A (ja) * 2010-03-31 2013-06-17 グラクソ グループ リミテッド キナーゼ阻害剤としてのイミダゾリル‐イミダゾール
WO2017151409A1 (en) 2016-02-29 2017-09-08 University Of Florida Research Foundation, Incorporated Chemotherapeutic methods

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9300141A (es) * 1992-01-13 1994-07-29 Smithkline Beecham Corp Compuestos de imidazol novedosos, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
US5916891A (en) 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
EP0624159B1 (en) * 1992-01-13 1998-11-25 Smithkline Beecham Corporation Pyridyl substituted imidazoles
WO1995003297A1 (en) 1993-07-21 1995-02-02 Smithkline Beecham Corporation Imidazoles for treating cytokine mediated disease
US5620999A (en) * 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
KR19990064117A (ko) * 1995-10-06 1999-07-26 폴락 돈나 엘. 항암 활성과 사이토킨 억제 활성을 갖는 치환된 이미다졸
US5717100A (en) * 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
US5965583A (en) 1997-04-24 1999-10-12 Ortho-Mcneil Pharmaceutical, Inc. Substituted imidazoles useful in the treatment of inflammatory disease
EP0988301B1 (en) 1997-06-12 2006-08-09 Aventis Pharma Limited Imidazolyl-cyclic acetals
WO1998057966A1 (en) 1997-06-19 1998-12-23 Smithkline Beecham Corporation Novel aryloxy substituted pyrimidine imidazole compounds
AU8757098A (en) 1997-06-30 1999-02-10 Ortho-Mcneil Pharmaceutical, Inc. 2-substituted imidazoles useful in the treatment of inflammatory diseases
TW517055B (en) 1997-07-02 2003-01-11 Smithkline Beecham Corp Novel substituted imidazole compounds
AR016294A1 (es) 1997-07-02 2001-07-04 Smithkline Beecham Corp Compuesto de imidazol sustituido, composicion farmaceutica que la contiene, su uso en la fabricacion de un medicamento y procedimiento para supreparacion
AU8381098A (en) 1997-07-02 1999-01-25 Smithkline Beecham Corporation Novel cycloalkyl substituted imidazoles
FR2772377B1 (fr) 1997-12-12 2000-01-07 Synthelabo Derives de 1-(1-h-imidazol-2-yl)pyrrolidines et 1-(1-h-imidazol-2-ylpiperidines), leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
AU8801598A (en) 1999-01-25
BR9810955A (pt) 2000-09-26
KR20010013215A (ko) 2001-02-26
PT993456E (pt) 2005-01-31
CN1261885A (zh) 2000-08-02
CA2291758A1 (en) 1999-01-14
ATE275557T1 (de) 2004-09-15
TW429258B (en) 2001-04-11
US6300347B1 (en) 2001-10-09
JP2001506280A (ja) 2001-05-15
CO4940462A1 (es) 2000-07-24
SK186599A3 (en) 2000-06-12
EP1396491A2 (en) 2004-03-10
EP1396491A3 (en) 2004-06-30
AU744411B2 (en) 2002-02-21
IL133034A0 (en) 2001-03-19
EP0993456B1 (en) 2004-09-08
WO1999001449A1 (en) 1999-01-14
JP3704362B2 (ja) 2005-10-12
NO996429D0 (no) 1999-12-23
EP0993456A1 (en) 2000-04-19
ZA985656B (en) 1998-12-30
GB9713726D0 (en) 1997-09-03
TR199903278T2 (en) 2000-07-21
DE69826127D1 (de) 2004-10-14
PE99999A1 (es) 1999-11-01
DE69826127T2 (de) 2005-09-29
HUP0003351A2 (hu) 2001-06-28
ID23385A (id) 2000-04-20
HUP0003351A3 (en) 2002-01-28
RU2214408C2 (ru) 2003-10-20
ES2226164T3 (es) 2005-03-16
NZ501275A (en) 2002-04-26
AR014886A1 (es) 2001-04-11
PL337057A1 (en) 2000-07-31

Similar Documents

Publication Publication Date Title
ATE275557T1 (de) 2-substituierte 4,5-diarylimidazole
NO2006016I1 (no) 7,8,9,10-tetrahydro-6H-6,10-metanoazepinoÄ4,5-gÜkinoksalintartrat
ID29241A (id) Turunan-turunan kinolin teranelasi-1,2
DE69933287D1 (de) 12,13-modifizierte epothilon-derivate
DK1000048T3 (da) Substituerede 1,2,3,4-tetrahydronapthalenderivater
ID21413A (id) Turunan-turunan 1,3,8,-triaza-spiro (4,5) dekan-4-on
TR199800988A3 (tr) 5&#39; Deoksi-Sitidin türevleri.
ID26909A (id) Turunan-turunan 1,3,4-oksadiazolon
DK1149106T3 (da) 4,5-azolo-oxindoler
MA24551A1 (fr) W.c.
DK1068200T3 (da) 2,4,4-trisubstituerede-1,3-dioxolanfungicider
ID24047A (id) Turunan 5-tersubstitusi-3-oksaziazolil 1,6-naftiridin-2 1h-on
ID26368A (id) Turunan-turunan 2 deoksi higromisin
ES1036909Y (es) Pupitre infantil.
DK0966464T3 (da) Substituerede 2,4-diaminopyrimidiner
ES1037395Y (es) Tendedero antilluvia.
FI971570A0 (fi) Styrsystem foer foerbraenningsluften i en ackumulerande, vedeldad eldstad
ID19473A (id) 24-homo-26,27-heksafluoro-kolkalsiferol
FI971391A0 (fi) Koppling laemplig foer spaenningsarbete, saerskilt koppling foer ljusbaogs- eller oeverstoemsskydd
FI971438A0 (fi) Koppling laemplig foer spaennings- eller spaenningsfri arbete, saerskilt koppling foer ljusbaogs- eller oeverstoemsskydd
ES1036324Y (es) Cose-papeles mejorado.
ES1038416Y (es) Gregadero mejorado.
ES1036948Y (es) Carpeta-atril mejorada.
ES1038270Y (es) Anillo-grafo.
ES1036787Y (es) Carterita-neceser.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application